



Key Information Document ('KID')

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Name of Fund: **L&G Pharma Breakthrough UCITS ETF**

Share class name: **USD Accumulating ETF**

Manufacturer name: LGIM Managers (Europe) Limited, part of the Legal & General Group

Share class ISIN: IE00BF0H7608

This PRIIP is authorised in Ireland

Website: www.lgim.com

Telephone: +44 (0) 203 124 3180

Regulator: Central Bank of Ireland

Production date: 2025-02-25

What is this product?

Type: This investment fund is a sub-Fund of Legal & General UCITS ETF Plc (the "**Company**"), an umbrella investment company with variable capital and segregated liability between Funds. The Fund is authorised in Ireland and regulated by the Central Bank of Ireland.

Term: There is no fixed maturity date.

Objectives: The Fund is a passively managed exchange traded Fund that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the "**Index**"), subject to the deduction of the ongoing charges and other costs associated with operating the Fund.

The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices.

Shares in this Share Class (the "**Shares**") are denominated in USD and can be bought and sold on stock exchanges by ordinary investors using an intermediary (e.g. a stockbroker). In normal circumstances, only Authorised Participants may buy and sell Shares directly with the Company. Authorised Participants may redeem their Shares on demand in accordance with the "Dealing Timetable" published on <http://www.lgim.com>.

The index is comprised of bio-technology companies which are publically traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An "orphan drug" is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publically traded) and (2) it is sufficiently "liquid" (a measure of how actively its shares are traded on a daily basis). The Index will exclude companies which are constituents of the ESG Exclusions Enhanced Index, namely companies that (i) have severe controversies, (ii) are persistent violators of the UN Global Compact, and/or (iii) are involved, to a certain degree, in harmful activities as determined in the Index Methodology, available at: www.solactive.com. The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.

The Fund will primarily invest directly in the securities represented in the Index in similar proportions to their weightings in the Index. The fund may also invest in (1) bio-technology companies that are not constituents of the Index that have similar risk and performance characteristics to the companies contained in the Index and (2) financial derivative instruments ("FDIs") (i.e. investments the prices of which are based on the companies contained in the Index and/or such other bio-technology companies). Adjustments to the Fund's portfolio, including as a result of a reconstitution of the Index, will incur transaction costs.


This Share Class does not intend to pay dividends. Any income which may result from the Fund's investments will be re-invested into the Fund.

The depositary of the Fund is the Bank of New York Mellon SA/NV, Dublin Branch. Further information about the Fund and the share class can be obtained from the Company's prospectus and the annual and semi-annual reports, which are available, in addition to the latest prices for the share class and details of any other share classes, free of charge at: www.lgim.com.

Intended retail investor: The Fund is designed for investors looking to grow their money in an investment which can form part of their existing savings portfolio. Although investors can take their money out at any time, the Fund may not be appropriate for those who plan to withdraw their money within five years.

The Fund is not designed for investors who cannot afford more than a minimal loss of their investment.

What is the risk and what could I get in return?



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 4 out of 7, which is a medium risk class. This classification rates the potential losses from future performance at a medium level, and poor market conditions could impact the value of your investment. Any other risks materially relevant to the PRIIP not included in the summary risk indicator are described in the Fund supplement and/or Prospectus. The lowest category does not mean risk free.

Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production.

The value of the Fund may be affected by risks not in the SRI, including failure of a counterparty, custodian, issuer or index provider and derivative use.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Be aware of currency risk. You may receive payments in a different currency, so the final return you will get depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

The Fund is not covered by an investor compensation scheme.

Performance scenarios

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product with input from benchmark(s)/proxy over the last 10 years. Markets could develop very differently in the future.

Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

Investment USD 10,000.00			
Scenarios		1 year	5 years (Recommended holding period)
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress scenario*	What you might get back after costs	2,140 USD	3,210 USD
	Average return each year	-78.6%	-20.3%
Unfavourable scenario**	What you might get back after costs	7,890 USD	7,500 USD
	Average return each year	-21.1%	-5.6%
Moderate scenario***	What you might get back after costs	10,250 USD	12,290 USD
	Average return each year	2.5%	4.2%
Favourable scenario****	What you might get back after costs	14,020 USD	17,230 USD
	Average return each year	40.2%	11.5%

* The Stress scenario shows what you might get back in extreme market circumstances.

** The Unfavourable scenario was simulated based on the appropriate benchmark used for an investment between 08-2021 and 12-2024.

*** The Moderate scenario was simulated based on the appropriate benchmark used for an investment between 04-2018 and 04-2023.

**** The Favourable scenario was simulated based on the appropriate benchmark used for an investment between 10-2016 and 10-2021.

This table shows the money you could get back over the next 5 year(s), under different scenarios, assuming that you invest 10,000.00 USD.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What happens if LGIM Managers (Europe) Limited is unable to pay out?

If LGIM Managers (Europe) Limited defaults, investors in the Fund would not face any financial losses. However, the value of an investment and any income taken from it is not guaranteed and can go down as well as up, you may not get back the amount you originally invested. The fund is not covered by an investor compensation scheme.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for the holding period(s). They include potential early exit penalties. The figures assume you invest 10,000.00 USD. The figures are estimates and may change in the future.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10,000.00 is invested.

Investment USD 10,000.00	If you cash in after 1 year	If you cash in after 5 years
Total costs	60 USD	372 USD
Impact on return (RIY) per year (*)	0.6%	0.6%

(*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 4.8% before costs and 4.2% after costs.

Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- What the different cost categories mean.

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0.00% There is no entry fee for this product.	0 USD
Exit costs	0.00% There is no exit fee for this product.	0 USD
Ongoing costs taken each year		
Management fees and other administrative or operating costs	0.49% of the value of your investment per year.	49 USD
Transaction costs	0.11% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	11 USD
Incidental costs taken under specific conditions		
Performance fees and carried interest	0.00% There is no performance fee for this product.	0 USD

How long should I hold it and can I take my money out early?

An investor can hold their investment for any time period but 5 year(s) is recommended.

The recommended holding period of 5 years has been selected for illustrative purposes for a product with a medium to long-term investment horizon. There is no minimum (or maximum) holding period for the fund and you can redeem your investment any time in accordance with the fund prospectus, however you may receive less than expected if you cash in earlier than the RHP. If you are in any doubt about the suitability of the product to meet your needs, you should seek professional advice. The Shares can be sold by ordinary investors using an intermediary (e.g. a stockbroker) when the markets on which they trade are open. An intermediary is likely to apply a commission to purchases and sales. Please see "What are the costs?" section for details of any exit fees.

The above mentioned period has been defined in accordance to the product characteristics.

How can I complain?

Complaints can be made in writing to LGIM Managers (Europe) Ltd, 70 Sir John Rogerson's Quay, Dublin 2, D02 R296, Ireland or by submitting your complaint via the contact us section of the website <https://www.legalandgeneral.com/contact-us/> or by email to complaints@lgim.com.

Other relevant information

Further information about the Fund including 5 years of past performance history and previous performance scenarios required under PRIIPs regulation can be found at www.lgim.com. Past performance is not a guide to future performance and future returns could be significantly worse than shown. This Key Investor Document is updated at least every 12 months. If you are in any doubt about the action you should take, you should seek independent financial advice.